AIM: To review and assess the evidence related to cetuximab treatment in metastatic colorectal cancer(mCRC) with regard to KRAS status.METHODS: PubMed, EMBASE, Cochrane database and American Society of Clinical Oncolo...AIM: To review and assess the evidence related to cetuximab treatment in metastatic colorectal cancer(mCRC) with regard to KRAS status.METHODS: PubMed, EMBASE, Cochrane database and American Society of Clinical Oncology meeting abstracts were searched for randomized controlled trials(RCTs) reporting the effect of KRAS status on efficacy of chemotherapy regimen with or without cetuximab in mCRC. Baseline information such as sex and age was summarized from the included studies.Hazard ratios of progression-free survival(PFS) and overall survival(OS) as well as objective response based on KRAS status were extracted for analysis.RESULTS: A total of 8 RCTs with 6780 patients were included. The combined analysis showed that cetuximab failed to improve the OS and PFS in patients with mCRC.However, in subgroup analysis, the pooled data showed that addition of cetuximab to irinotecan containing chemotherapy regimen was sufficient to improve OS and PFS in wild-type KRAS mCRC patients, but not in patients with mutant-type KRAS. The addition of cetuximab increased the incidence of adverse events such as diarrhea, rash, skin toxicity/rash, and nausea and vomiting. There was no significant publication bias existing in the included studies.CONCLUSION: The clinical benefit of cetuximab was only confirmed in patients with wild-type KRAS. KRAS status could be considered a biomarker of efficacy of cetuximab.展开更多
1文献来源
Makoto M, Akira I, Kunihiko K, et al. Gefitinib or chemotherapy for non-small cell lung cancerwith mutated EGFR [J]. N Engl J Med, 2010, 362（25） ： 2380-2388.
Three-dimensional(3D)printing technology,as a novel technical method,can convert conventional computed tomography(CT)or magnetic resonance imaging(MRI)scans to computer-aided design files and develop a 2D spatial stru...Three-dimensional(3D)printing technology,as a novel technical method,can convert conventional computed tomography(CT)or magnetic resonance imaging(MRI)scans to computer-aided design files and develop a 2D spatial structure into a 3D imaging structure.In recent years,the technology has been widely used in numerous areas,including head and neck surgery,orthopedics,and bio-medicinal research.This article uses examples of 3D printed tumor models to develop Response Evaluation Criteria In Solid Tumors(RECIST)standards to evaluate the changes in tumors.RECIST standard is currently recognized as the standard for assessment of chemotherapy.Under the RECIST standard,changes occurring in tumors before and after the surgery,are evaluated.The assessment depends upon a CT evaluation of the changes in the lesions with the largest diameters.In addition,the disease progression and stability of remission is also assessed.Three-dimensional printing technology is more intuitive in the evaluation of changes to human tumors following chemotherapy and targeted therapy.However,a few reports are available.展开更多
目的采用Meta分析考察西达本胺联合标准化疗治疗外周T细胞淋巴瘤的临床疗效。方法搜索了中国知网、万方、维普、Web of Science、PubMed、Cochrane Library、Embase等数据库,检索文献发表时间为从数据库建库到2023年6月的西达本胺联合...目的采用Meta分析考察西达本胺联合标准化疗治疗外周T细胞淋巴瘤的临床疗效。方法搜索了中国知网、万方、维普、Web of Science、PubMed、Cochrane Library、Embase等数据库,检索文献发表时间为从数据库建库到2023年6月的西达本胺联合标准化疗治疗外周T细胞淋巴瘤的试验,应用Cochrane中心提供的Revman 5.4软件对数据进行统计学处理分析。结果筛选符合标准的文献为10篇,共494例患者。西达本胺在外周T细胞淋巴瘤治疗中可显著改善完全缓解率、客观缓解率、1年生存率、1年无进展生存率,与标准化疗间的差异具有统计学意义。结论对于外周T细胞淋巴瘤患者,西达本胺联合化疗在完全缓解率、客观缓解率、1年生存率、1年无进展生存率均优于单纯化疗。展开更多
Objective To investigate the therapeutic effects of haploidentical hematopoietic stem - cell transplantation ( Haplo - PBSCT) for acute myeloid leukemia in first relapse after complete remission by standard induction ...Objective To investigate the therapeutic effects of haploidentical hematopoietic stem - cell transplantation ( Haplo - PBSCT) for acute myeloid leukemia in first relapse after complete remission by standard induction chemotherapy. Methods Eighty - nine cases of AML in first relapse after complete remission by standard DA展开更多
文摘AIM: To review and assess the evidence related to cetuximab treatment in metastatic colorectal cancer(mCRC) with regard to KRAS status.METHODS: PubMed, EMBASE, Cochrane database and American Society of Clinical Oncology meeting abstracts were searched for randomized controlled trials(RCTs) reporting the effect of KRAS status on efficacy of chemotherapy regimen with or without cetuximab in mCRC. Baseline information such as sex and age was summarized from the included studies.Hazard ratios of progression-free survival(PFS) and overall survival(OS) as well as objective response based on KRAS status were extracted for analysis.RESULTS: A total of 8 RCTs with 6780 patients were included. The combined analysis showed that cetuximab failed to improve the OS and PFS in patients with mCRC.However, in subgroup analysis, the pooled data showed that addition of cetuximab to irinotecan containing chemotherapy regimen was sufficient to improve OS and PFS in wild-type KRAS mCRC patients, but not in patients with mutant-type KRAS. The addition of cetuximab increased the incidence of adverse events such as diarrhea, rash, skin toxicity/rash, and nausea and vomiting. There was no significant publication bias existing in the included studies.CONCLUSION: The clinical benefit of cetuximab was only confirmed in patients with wild-type KRAS. KRAS status could be considered a biomarker of efficacy of cetuximab.
文摘1文献来源
Makoto M, Akira I, Kunihiko K, et al. Gefitinib or chemotherapy for non-small cell lung cancerwith mutated EGFR [J]. N Engl J Med, 2010, 362（25） ： 2380-2388.
基金Supported by a grant from the National Natural Science Foundation of China(No.81702622)。
文摘Three-dimensional(3D)printing technology,as a novel technical method,can convert conventional computed tomography(CT)or magnetic resonance imaging(MRI)scans to computer-aided design files and develop a 2D spatial structure into a 3D imaging structure.In recent years,the technology has been widely used in numerous areas,including head and neck surgery,orthopedics,and bio-medicinal research.This article uses examples of 3D printed tumor models to develop Response Evaluation Criteria In Solid Tumors(RECIST)standards to evaluate the changes in tumors.RECIST standard is currently recognized as the standard for assessment of chemotherapy.Under the RECIST standard,changes occurring in tumors before and after the surgery,are evaluated.The assessment depends upon a CT evaluation of the changes in the lesions with the largest diameters.In addition,the disease progression and stability of remission is also assessed.Three-dimensional printing technology is more intuitive in the evaluation of changes to human tumors following chemotherapy and targeted therapy.However,a few reports are available.
文摘目的采用Meta分析考察西达本胺联合标准化疗治疗外周T细胞淋巴瘤的临床疗效。方法搜索了中国知网、万方、维普、Web of Science、PubMed、Cochrane Library、Embase等数据库,检索文献发表时间为从数据库建库到2023年6月的西达本胺联合标准化疗治疗外周T细胞淋巴瘤的试验,应用Cochrane中心提供的Revman 5.4软件对数据进行统计学处理分析。结果筛选符合标准的文献为10篇,共494例患者。西达本胺在外周T细胞淋巴瘤治疗中可显著改善完全缓解率、客观缓解率、1年生存率、1年无进展生存率,与标准化疗间的差异具有统计学意义。结论对于外周T细胞淋巴瘤患者,西达本胺联合化疗在完全缓解率、客观缓解率、1年生存率、1年无进展生存率均优于单纯化疗。
文摘Objective To investigate the therapeutic effects of haploidentical hematopoietic stem - cell transplantation ( Haplo - PBSCT) for acute myeloid leukemia in first relapse after complete remission by standard induction chemotherapy. Methods Eighty - nine cases of AML in first relapse after complete remission by standard DA
